Matinas BioPharma s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
25.03.2024 - Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel Results build on data from prior in vivo study of . Seite 1
Study results show reduction in tumor size comparable to IV docetaxel and no systemic toxicityBEDMINSTER, N.J., Nov. 07, 2023 Matinas BioPharma Holdings, Inc. , a clinical-stage.